1 / 10

Daclatasvir + Sofosbuvir in Genotype 3 ALLY-3 Study

This study evaluates the efficacy and safety of daclatasvir and sofosbuvir in the treatment of hepatitis C genotype 3 patients, both those who are treatment-naïve and those who have experienced previous treatment. The study provides detailed information on drug dosing, patient characteristics, treatment outcomes, and adverse events.

jlarry
Télécharger la présentation

Daclatasvir + Sofosbuvir in Genotype 3 ALLY-3 Study

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 3 Treatment-Naïve and Treatment-Experienced Daclatasvir + Sofosbuvir in Genotype 3ALLY-3 Study Nelson DR, et al. Hepatology 2015;61:1127-35.

  2. Daclatasvir + Sofosbuvir for HCVGT 3ALLY-3 Trial: Study Features Source: Nelson DR, et al. Hepatology2015;61:1127-35.

  3. Daclatasvir + Sofosbuvir for HCV GT 3ALLY-3 Trial: Design 0 12 24 Week Daclatasvir + Sofosbuvir Treatment-Naïve n=101 SVR12 Treatment-Experienced n=51 Daclatasvir + Sofosbuvir SVR12 Drug DosingDaclatasvir: 60 mg once dailySofosbuvir: 400 mg once daily Source: Nelson DR, et al. Hepatology 2015;61:1127-35.

  4. Daclatasvir + Sofosbuvir for HCV GT 3ALLY-3 Trial: Patient Characteristics a Intolerant of therapy (n=6), virologic breakthrough (n=2), HCV never undetectable on treatment (n=2) Source: Nelson DR, et al. Hepatology 2015;61:1127-35.

  5. Daclatasvir + Sofosbuvir for HCV GT 3ALLY-3 Trial: Results ALLY-3: SVR12, by Baseline Characteristics Status 58/62 128/142 7/10 40/44 95/108 55/60 80/92 77/90 Male Female <65 ≥65 <800K ≥800K CC Non-CC Note: SVR 12 based on HCV RNA less than lower limit of quantitation (25 IU/mL), detectable or undetectable Source: Nelson DR, et al. Hepatology 2015;61:1127-35.

  6. Daclatasvir + Sofosbuvir for HCV GT 3ALLY-3 Trial: Results ALLY-3: SVR12, by Cirrhosis Status 91/101 44/51 135/152 Source: Nelson DR, et al. Hepatology 2015;61:1127-35.

  7. Daclatasvir + Sofosbuvir for HCV GT 3ALLY-3 Trial: Results ALLY-3: SVR12, by Cirrhosis Status 73/75 32/34 11/19 9/13 20/32 73/75 11/19 32/34 9/13 105/109 Note:11 had missing or inconclusive findings for cirrhosis and not included in denominators Source: Nelson DR, et al. Hepatology 2015;61:1127-35.

  8. Daclatasvir + Sofosbuvir for HCV GT 3ALLY-3 Trial: Adverse Events Source: Nelson DR, et al. Hepatology 2015;61:1127-35.

  9. Daclatasvir + Sofosbuvir for HCV GT 3ALLY-3 Trial: Conclusion Source: Nelson DR, et al. Hepatology 2015;61:1127-35.

  10. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.

More Related